Filter Results:
(350)
Show Results For
- All HBS Web
(350)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(350)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
- 27 Aug 2008
- Research & Ideas
Creating Leaders for Science-Based Businesses
Ph.D. in biology and a former biology professor at Harvard, has also had a 25-year career in drug development and biotech companies, leading both R&D and business functions. She teaches the MBA elective Inventing Breakthroughs and... View Details
- March 2018 (Revised July 2018)
- Case
Greenlight Biosciences: In Search of Impact Investment
By: Michael Chu, Annelena Lobb and Joni Coughlin
Greenlight Biosciences, a biotech company, is in search of impact investment for its next round of financing. View Details
Keywords: Impact Investment; Investment; Environmental Sustainability; Financing and Loans; Biotechnology Industry
Chu, Michael, Annelena Lobb, and Joni Coughlin. "GreenLight Biosciences: In Search of Impact Investment." Harvard Business School Case 318-072, March 2018. (Revised July 2018.)
- 14 Jul 2023
- Blog Post
Harvard Business School Announces Its 2023-2024 Blavatnik Fellows
offers HBS alumni and Harvard-affiliated postdocs the opportunity to work closely with leading biotech industry and biomedical authorities, receive mentorship, and join a community of entrepreneurs shaping the future of science. To date,... View Details
- April 2001 (Revised January 2003)
- Case
Robert Shapiro and Monsanto
Traces Monsanto's efforts to become a global biotech powerhouse under Shapiro's leadership. Examines how his crusade to save the world through genetic modification foundered. View Details
Keywords: Genetics; Supply Chain Management; Alliances; Global Strategy; Cross-Cultural and Cross-Border Issues; Biotechnology Industry
Watkins, Michael D., and Ann Leamon. "Robert Shapiro and Monsanto." Harvard Business School Case 801-426, April 2001. (Revised January 2003.)
- 17 Jun 2019
- Blog Post
Why I Would Have Applied to the MS/MBA Biotechnology: Life Sciences Program
definitely would have applied, for these reasons: Leadership As mentioned, both scientific and managerial skillsets are required to commercialize biotech discoveries and realize its benefits for many patients. I would have viewed the... View Details
- 14 Jul 2021
- Blog Post
From Colombia to the District of Columbia: Making an Impact with Paulina Llano (MBA 2022)
herself in Boston at Harvard Business School and is spending the summer interning for a Cambridge-based pharmaceutical and biotech company that has become a household name – Moderna. The contributions Llano will be making to the team and... View Details
Keywords: Health Care
- 12 Dec 2023
- Blog Post
Bridging Science and Business: My Summer Internship at Eli Lilly
Johnson's JJDC to AI and Data Strategy at Moderna, and even philanthropic efforts in Alzheimer's research within Bill Gates' private investment office, my classmates and I didn't just scatter across the biotech industry—we purposefully... View Details
- 13 Nov 2006
- Research & Ideas
Science Business: What Happened to Biotech?
Thirty years ago it appeared as if biotech would not only revolutionize healthcare, but also radically improve the very process of R&D itself. This hasn't happened. Though some firms such as Amgen have created dramatic breakthroughs,... View Details
- 20 Jun 2019
- Blog Post
What is the MS/MBA Biotechnology: Life Sciences Program? A Q&A with Bill Anderson, Senior Lecturer on Stem Cell and Regenerative Biology
this field. Furthermore, these advances raise a host of ethical issues in terms of diseases targeted, types of therapies, and accessibility. Given the rich experience of translational science in the Harvard system (Cambridge, Longwood, and the affiliated hospitals),... View Details
- January 1998 (Revised September 2001)
- Case
Genset: 1989
By: Paul A. Gompers and Amy Burroughs
Discusses the start-up strategy at Genset, a French biotech firm. Pascal Brandys, a venture capitalist, and Marc Vasseur, a leading French scientist, must decide how to proceed. Future real options are central to the strategy. View Details
Gompers, Paul A., and Amy Burroughs. "Genset: 1989." Harvard Business School Case 298-070, January 1998. (Revised September 2001.)
- Career Coach
Mansi Raythatha
Having both worked hands-on in these positions, as well as led recruitment into the US, Europe and Asia as head of Merck's Global Leadership Development Program, Mansi can provide insights into how these industries recruit, what the job experience will look like, and... View Details
- 28 Oct 2010
- News
Lose manufacturing and you lose capacity for innovation
- 08 Feb 2021
- News
How To Successfully Pull Off a Dramatic Career Switch
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Biotechnology Industry; Switzerland; Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- 04 Jan 2011
- News
At Novartis, a winning formula
- 24 Jan 2017
- News
Call to Create Jobs, or Else, Tests Trump’s Sway
- Research Summary
Charitable Investing
He is working on the subject of why and how private foundations and public charities could buy securities in a private commercial venture if it furthered their charitable mission. For example, a MS foundation would buy stock in a start-up biotech venture... View Details
- 05 Oct 2022
- Video